Which contingent sequential screening protocol? [4]

Prenatal Diagnosis

Volumn 25, Issue 6, 2005, Pages 520-521

  Wright, Dave ^a   Bradbury, Ian ^b   Benn, Peter ^c   Cuckle, Howard ^d   Ritchie, Karen ^e  

^a UNIVERSITY OF PLYMOUTH   (United Kingdom)

^b UNIVERSITY OF ULSTER   (United Kingdom)

^c UNIVERSITY OF CONNECTICUT   (United States)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e NHS Quality Improvement ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DISEASE MARKER; DOWN SYNDROME; EARLY DIAGNOSIS; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HIGH RISK POPULATION; HUMAN; LETTER; MATERNAL CARE; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; SCREENING TEST; SECOND TRIMESTER PREGNANCY;

DOWN SYNDROME; FEMALE; GESTATIONAL AGE; HUMANS; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PRENATAL DIAGNOSIS;

EID: 21844480673     PISSN: 01973851     EISSN: None     Source Type: Journal    
DOI: 10.1002/pd.1147     Document Type: Letter

References (2)

1. Wald N, Rodeck C, Rudnicka A, Hackshaw A. 2004. Nuchal translucency and gestational age. Prenat Diagn 24(2): 150-151.
2. Wright D, Bradbury I, Benn P, Cuckle H, Ritchie K. 2004. Contingent screening for Down syndrome is an efficient alternative to non-disclosure sequential screening. Prenat Diagn 24(10): 762-766.